IJCS | Volume 33, Nº1, January / February 2019

75 Chart 4 - Frequency of use of anticoagulants regarding the CHA 2 DS 2 -VASC score in adult patients admitted with atrial fibrillation at a tertiary hospital in Salvador, Bahia, Brazil. KVA DOAC Antiplatelet agent alone No medication 26.5 55.9 2.9 16 21.3 20.7 12.5 68 56 41.4 25 4 13.3 27.6 50 12 9.3 10.3 100% 80% 60% 40% 20% 0% 0 1 2 14.7 12.5 25.6 60.5 4.7 9.3 30.3 57.6 6.1 6.1 26.8 51.8 21.4 6.3 37.5 37.5 18.8 3 4 5 6 7 8 o 9 CHA 2 DS 2 -VASC Geraldes et al. Oral anticoagulation in AF Int J Cardiovasc Sci. 2020;33(1):68-78 Original Article Table 2 - Multivariate logistic regression model for predictors of anticoagulant use in patients admitted with atrial fibrillation at a tertiary hospital in Salvador, Bahia, Brazil Variable OR (95% CI) p History of AF 3.13 (1.80 to 5.44) < 0.001 SAH 3.05 (1.66 to 5.62) < 0.001 HASBLED 0.50 (0.38 to 0.66) < 0.001 Table 3 - Multivariate logistic regression model for predictors of DOAC use in adult patients admitted with atrial fibrillation at a tertiary hospital Variable OR (95% CI) p Serum creatinine (mg/dL) 0.18 (0.06 to 0.52) 0.002 LA diameter (mm) 0.92 (0.87 to 0.97) 0.003 Biological valve prosthesis 0.12 (0.03 to 0.57) 0.007 CV (electrical or chemical) 2.02 (0.97 to 4.22) 0.060 Electrical or chemical CV; CV: electrical cardioversion; LA: left atrium. Table 4 - Frequency of inappropriate use of DOACs in 208 patients with atrial fibrillation, with indication for use of anticoagulants at a private tertiary hospital in Salvador, Bahia, Brazil DOAC used DOAC misuse frequency n (%) Contraindication for drug interaction n (%) Improper dose reduction n (%) Improper full dose n (%) Dabigatran (n = 60) 33 (55) 2 (3.3) 29 (67) 2/17 (11.8) Rivaroxaban (n = 119) 22 (18.5) 1 (0.8) 18 (48.6) 3/82 (3.6) Apixaban (n = 29) 8 (27.6) 2 (6.9) 6 (46.1) 0/16 (0)